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During human immunodeficiency virus entry, gp41
undergoes a series of conformational changes that in-
duce membrane fusion. Immediately prior to fusion,
gp41 exists in a prehairpin intermediate in which the N-
and C-peptide regions of gp41 are exposed. Rearrange-
ment of this intermediate into a six-helix bundle com-
posed of a trimeric coiled coil from the N-peptide region
(N-trimer) surrounded by three peptides from the C-
peptide region provides the driving force for membrane
fusion, whereas prevention of six-helix bundle forma-
tion inhibits viral entry. Because of its central role in
mediating viral entry, the N-trimer region of gp41 is a
key vaccine target. Extensive efforts to discover potent
and broadly neutralizing antibodies (Abs) against the
N-trimer region have, thus far, been unsuccessful. In
this study, we attached a potent C-peptide inhibitor that
binds to the N-trimer region to cargo proteins of various
sizes to examine the steric accessibility of the N-trimer
during fusion. These inhibitors show a progressive loss
of potency with increasing cargo size. Extension of the
cargo/C-peptide linker partially restores inhibitory po-
tency. These results demonstrate that the human immu-
nodeficiency virus defends its critical hairpin-forming
machinery by steric exclusion of large proteins and may
explain the current dearth of neutralizing Abs against
the N-trimer. In contrast, previous results suggest the
C-peptide region is freely accessible during fusion, dem-
onstrating that the N- and C-peptide regions are in
structurally distinct environments. Based on these re-
sults, we also propose new strategies for the generation
of neutralizing Abs that overcome this steric block.
Human immunodeficiency virus (HIV)1 entry is mediated by
the viral envelope (Env) glycoprotein. Env is initially produced
as gp160, which is proteolytically cleaved into non-covalently
associated transmembrane (gp41) and surface (gp120) sub-
units. gp120 is primarily involved in recognition of cellular
receptors, whereas gp41 is anchored in the viral membrane and
mediates membrane fusion. The gp41 ectodomain contains two
helical heptad repeat sequences (N- and C-peptide regions) (1,
2). Peptides corresponding to these helical regions (N- and
C-peptides) are dominant-negative inhibitors of HIV mem-
brane fusion (2, 3). Isolated N- and C-peptides form a six-helix
bundle (trimer-of-hairpins) when mixed in solution (4–6). In
this structure, three N-peptides form a central parallel trimeric
coiled coil (N-trimer) surrounded by three anti-parallel C-pep-
tides that nestle between neighboring N-peptides.
Based largely on these inhibitory and structural data, a
working model of HIV-1 membrane fusion has been proposed
(Fig. 1) (3, 5). Initial interaction of Env with its target cell
occurs via gp120 binding to CD4 and a coreceptor (typically
CCR5 or CXCR4). This binding induces a series of large con-
formational changes in gp120 that are propagated to gp41 via
the gp41-gp120 interface. At this stage, gp41 transiently
adopts an extended “prehairpin intermediate” conformation
that bridges both the viral and cellular membranes. This state
is believed to persist for at least 15 min (3, 7, 8) but eventually
collapses into a trimer-of-hairpins structure that pulls both
membranes into tight apposition and induces membrane fusion
(Fig. 1).
In this model, the prehairpin intermediate exposes the iso-
lated N-trimer, whereas the C-peptide region exists in an un-
known and possibly unstructured conformation remote from
the N-trimer (3). At this stage, the prehairpin intermediate is
vulnerable to binding of exogenous N- and C-peptides. Binding
of these peptide inhibitors denies access of the endogenous N-
or C-peptide regions to their appropriate intramolecular part-
ners, thwarting hairpin formation and membrane fusion. This
model predicts that any molecule that binds to the prehairpin
intermediate and disrupts association of the N- and C-peptides
will inhibit membrane fusion and has been successfully applied
to the development of several potent entry inhibitors (9–11).
Additionally, the gp41 prehairpin intermediate has several
promising features as an inhibitory target (12). Peptide mimics
of the N-trimer region have been structurally characterized at
high resolution (4–6). The interface between the N- and C-
peptides is highly conserved among diverse HIV strains of both
laboratory-adapted and clinical isolates (9). The N-trimer also
presents a long (100 Å) deep groove with an extensive binding
surface (4–6). These special properties have led many groups
to search for Abs that can disrupt this interface (reviewed in
Ref. 13).
C-peptide Inhibitors—Several peptide fusion inhibitors derived
from the N- and C-peptide regions of gp41 have been described (2,
3, 12, 14–16). The most potent are peptides derived from the C-
peptide region (e.g. C34, DP178/T20, T1249), which have low nM
IC50s against viral entry in cell-cell fusion (syncytia formation), and
viral infectivity assays (reviewed in Ref. 17). Several mutations
leading to T-20 resistance have been mapped to the N-peptide
region of gp41 (18), providing strong support that the N-trimer is
the primary target of C-peptide inhibitors.
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gp41 N-trimer as a Vaccine Target—As demonstrated by the
efficacy of C-peptide inhibitors, the N-trimer region of gp41 is a
very attractive candidate for vaccine efforts. Many such efforts
have been undertaken using various peptide mimics of the
N-trimer region (e.g. N-peptide, 5-helix, IZN36, and N35CCG-
N13) (17, 19–21). These efforts have produced a large number
of Abs with specific and high affinity binding to their targets
but weak and/or narrow neutralizing activity in standard viral
entry and spread assays. Interestingly, some of these anti-N-
trimer Abs can inhibit fusion if bound to a temperature-ar-
rested intermediate fusion state (19) or in the presence of
soluble CD4 (21). Currently, there are only two reported anti-
gp41 Abs that exhibit potent and broadly neutralizing activity,
2F5 and 4E10, which bind just outside the C-terminal border
of the C-peptide region, an area with uncertain structure
(reviewed in Ref. 22).
In this study, we tested the hypothesis that the N-trimer of
gp41 is sterically restricted in the prehairpin intermediate,
which may explain the current dearth of broadly neutralizing
Abs against this target (Fig. 1). All of the known fusion inhib-
itors that target this structure (e.g. C34, T-20, T-1249, D-
peptides) are small (40 residue) peptides and could circum-
vent such a steric block. We have constructed fusions of a well
characterized C-peptide inhibitor (C34) to a series of protein
cargoes of varying sizes to determine whether such a steric
block exists and, if so, to define its size cutoff. Our results
demonstrate that C-peptide fusion proteins lose inhibitory po-
tency with increasing size and that the N-trimer region of gp41
is likely to be poorly accessible to proteins as large as Abs.
These results have important implications for gp41 vaccine
design as well as for the production of second-generation C-
peptide entry inhibitors. This steric restriction also helps to
better define the conformation of the prehairpin intermediate.
MATERIALS AND METHODS
Reagents—Plasmids were obtained from the following sources: pET
vectors (Novagen), pMAL-c2G (New England Biolabs), pEBB-HXB2
and pEBB-JRFL (gifts from B. Chen) (23). Reverse phase HPLC was
performed using a C18 column (Vydac). All Ni affinity purifications
used His-Select HC nickel affinity gel (Sigma) or His-Select HC nickel
magnetic resin (Sigma). The National Institutes of Health AIDS Re-
search and Reference Reagent Program provided the following re-
agents: pNL4–3.Luc.R-E- (N. Landau), HeLa-CD4-LTR--galactosid-
ase cells (M. Emerman), HOS-CD4-fusin/CCR5 cells (N. Landau).
Protein Expression, Purification, and Characterization—C37-H6
(C37), derived from the HXB2 Env sequence, was expressed and puri-
fied as previously described (9). Proteins used in this study were bovine
pancreatic trypsin inhibitor (BPTI), human ubiquitin (Ub), sperm
whale myoglobin (Mb), enhanced green fluorescent protein (GFP;
Clontech), and Escherichia coli maltose-binding protein (MBP; New
England Biolabs). Linker sequences were Ser4Gly2 for BPTI-C37,
Ub-C37, and GFP-C37 and Ser5Gly2 for Mb-C37 and MBP-C37 (linker
sequences are slightly different for cloning reasons). The extended
linker constructs had the following linker sequences: SSS(GGGS)3-
SSSGG (MBP1-C37) and SSS(GGGS)3S(GGGS)3SSSGG (MBP2-C37).
The DNA encoding each protein was cloned into the following plasmids:
pET9a (for BPTI-C37, Ub-C37, Mb-C37, and GFP-C37), pET20b (for
BPTI-H6, Ub-H6, Mb-H6, and GFP-H6); pMAL-c2G (for MBP-H6,
MBP-C37, MBP1-C37, and MBP2-C37). Proteins were expressed in
BL21(DE3)pLysS (Novagen) for pET9a and pET20b vectors and XL1-
Blue (Stratagene) for pMal-c2G vectors. All proteins have C-terminal
His tags (His6) and were purified using Ni affinity chromatography.
BPTI required refolding after expression for correct formation of disul-
fide bonds. Briefly, after Ni affinity purification, BPTI-C37-H6 and
BPTI-H6 were reduced with 100 mM -mercaptoethanol at pH 8 and
dialyzed into 5% acetic acid. The proteins were air oxidized in the pres-
ence of a 1:10 ratio of oxidized:reduced glutathione at pH 8, 4 °C for 24 h.
The correctly folded proteins were isolated using reverse phase HPLC and
were confirmed by near-UV circular dichroism (Aviv 62DS) and measure-
ment of trypsin inhibiting activity as previously described (24).
Cys-Gly-Gly-Asp-IZN36 (10) was cloned into pET14b and ex-
pressed in BL21(DE3)pLysS. IZN36 was purified from inclusion bod-
ies (solubilized in 6 M GuHCl) using Ni affinity chromatography. The
protein was then dialyzed into 5% acetic acid and purified by reverse
phase HPLC. This material was reduced with TCEP (Pierce) and
biotinylated at its unique Cys residue using Biotin-HPDP (Pierce).
After biotinylation, the His tag was removed by thrombin cleavage
(Novagen), and the cleaved product was purified by reverse phase
HPLC. The sequence of the final product is GSHMCGGDIKKEI-
EAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTV-
WGIKQLQARIL.
All protein masses were confirmed by matrix-assisted laser desorp-
tion ionization or electrospray mass spectrometry (University of Utah
Core Facility). All proteins were judged 98% pure by SDS-PAGE.
Protein concentrations were measured by UV absorbance at 280 nm
(25).
Surface Plasmon Resonance (SPR) Analysis—Binding experiments
were performed using a Biacore 2000 optical biosensor (University of
Utah Protein Interaction Core Facility) equipped with research-grade
CM5 sensor chips (Biacore). A standard coupling protocol was employed
to immobilize streptavidin (SA; Pierce) (26). Biotinylated IZN36 was
captured on a SA surface, and free SA surfaces served as references.
Binding analysis of C37 and C37 fusion proteins was performed at
25 °C with a data collection rate of 2.5 Hz. The binding buffer (phos-
phate-buffered saline; Invitrogen)  0.005% P20 detergent (Biacore) 
1 mg/ml bovine serum albumin (fraction V; Fisher)) was prepared,
vacuum filtered, and degassed immediately prior to use. Stock solutions
of C37, C37 fusion proteins, and corresponding control proteins (with-
out C37) were prepared in binding buffer at 100 nM. Protein binding
was analyzed by injecting samples for 1 min over the IZN36 and
reference surfaces using KINJECT at a flow rate of 50–100 l/min. The
dissociations were monitored for 3 min. The IZN36 surfaces were com-
pletely regenerated using one 3-s pulse of 6 M guanidine-HCl or three
6-s pulses of 0.1% SDS.
Data from the reference flow cells were subtracted to remove sys-
tematic artifacts that occurred in all flow cells (27). The data were
normalized to the highest point in the response curve to facilitate
comparison. Binding at one concentration was analyzed using a 1:1
binding model in CLAMP (28), assuming enough information from the
curvature of the responses to determine the approximate kinetic pa-
rameters for the reactions (29).
Cell-cell Fusion and Viral Infectivity Assay—Cell-cell fusion was
monitored as previously described (30). Briefly, HXB2 Env-expressing
Chinese hamster ovary cells (gift fromM. Krieger (31)) were mixed with
HeLa-CD4-LTR--galactosidase cells in the presence of inhibitors for
20 h at 37 °C. Syncytia were stained with 5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-gal) (Invitrogen) and counted.
Viral infectivity was measured as previously described (9). Briefly,
pseudotyped viruses were produced by co-transfecting 293T cells using
FuGENE (Roche Applied Science) with pNL4–3.Luc.R-E- and either
pEBB-HXB2 or pEBB-JRFL. After 36–48 h, viral supernatants were
collected and sterile filtered. HXB2 or JRFL pseudotyped virus was
added to HOS-CD4-fusin or HOS-CD4-CCR5 cells, respectively, in the
presence of inhibitors. HXB2 assays included 20 g/ml DEAE-dextran
(23). After 12 h, virus and inhibitor were removed and replaced with
fresh media. Cells were lysed 40–44 h after infection using Glo lysis
buffer (Promega), and luciferase activity was measured using Bright-
Glo (Promega). IC50 values for both assays were calculated by fitting
data to the equation, y  k/(1 [inhibitor]/IC50), where y is the normal-
ized number of syncytia or luciferase activity and k is the scaling
constant (k  1 for syncytia assay and is floated for viral infectivity
assay, see Fig. 2B legend).
Assays for Inhibitor Proteolysis and Precipitation—C37 fusion inhib-
itors were incubated in tissue culture medium (Dulbecco’s modified
Eagle’s medium 10% fetal bovine serum; Invitrogen) at 37 °C for 20 h.
Proteins were purified from the medium by a 1-h incubation at room
temperature with magnetic Ni affinity beads. The resin was washed 3
with phosphate-buffered saline, and proteins were eluted by boiling in
LDS sample buffer (Invitrogen). Eluted samples were separated by
SDS-PAGE and visualized with SimplyBlue stain (Invitrogen). Unpu-
rified media samples were analyzed before and after centrifugation (10
min. at 18,000 g) by Western blot using polyclonal rabbit anti-His tag
Ab (Abcam) and SuperSignal West Pico substrate (Pierce), as well as
visually analyzed for precipitate.
RESULTS
Production of Fusion Proteins—To test for steric constraints
in accessing the gp41 N-trimer region, we constructed a series
of inhibitors containing a C-peptide attached to cargo proteins
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of various sizes (Fig. 1). The cargo partners used in this study
were selected for the following properties: monomeric, soluble,
globular, stable, tolerant to C-terminal additions, and free of
nonspecific peptide binding. Cargo proteins meeting these in-
clusion criteria and used in this study range from 6 to 41 kDa
(Table I). For these studies, C37 (9), the recombinant His-
tagged version of the previously characterized synthetic pep-
tide C34 (30, 32), was used as the reference inhibitor. In each
fusion protein, C37 is connected at its N terminus to the C
terminus of the cargo by a flexible 6- or 7-residue Ser/Gly
linker. This linker was designed to be long enough to allow the
proper orientation of C37 as it binds to the N-trimer but short
enough for the attached cargo to prevent access to an occluded
binding site. The N terminus of C37 was chosen for attachment
of cargo because this attachment site points away from the
membrane (whereas the C terminus of C37 is expected to be
near the viral membrane and, therefore, less accessible; see
Fig. 1). For each fusion protein, a matching control protein
lacking C37 was also produced.
Size and Inhibitory Potency Are Inversely Correlated—The
inhibitory potency of each inhibitor was tested using a cell-cell
fusion (syncytia) assay utilizing HXB2 Env and two viral in-
fectivity assays utilizing either HXB2 (X4) or JRFL (R5) Envs
(Table I, Fig. 2). C37 shows high potency inhibition in all
assays (IC50  0.85–8.2 nM). Inhibition is slightly weaker than
seen with C34 (30), as expected from the loss of helix-stabiliz-
ing synthetic blocking groups found in C34. For reference, the
anti-gp41 Abs 2F5 and 4E10 have reported IC50 values of
0.2–7 nM against HXB2/IIIB laboratory strains in cell-cell
and viral infectivity assays similar to those used in this study
(33, 34).
The smallest fusion protein, BPTI-C37, also displays high
potency in both assays, very similar to C37, demonstrating that
our C37-cargo linker does not interfere with inhibitory activity.
Ub-C37 is a slightly weaker (2.5–5.5-fold) inhibitor than C37,
whereas Mb-C37 and GFP-C37 both show more substantial
(21–65-fold) reductions in potency in both assays. MBP-C37
shows the most dramatic change with a 75–228-fold drop in
potency. None of the control proteins (cargo without C37 pep-
tide) inhibits at up to 1 M (10 M for MBP with JRFL Env) in
either assay (data not shown).
In general, the cell-cell fusion and viral infectivity assays
show similar losses of activity with increasing size of the in-
hibitors, with a slightly more pronounced effect on cell-cell
fusion and JRFL-mediated viral entry. For HXB2 Env we ob-
served up to a 4-fold greater potency in cell-cell fusion versus
viral infectivity as seen in studies of other fusion inhibitors (2,
11, 30, 35). As expected, inhibitors were less potent against the
primary isolate JRFL in the viral infectivity assay. For most of
the inhibitors, the viral infectivity data show a reproducible
increase in infectivity (above the uninhibited values) at low
inhibitor concentrations (see the legend to Fig. 2B). This “over-
shoot” has also occasionally been seen in other studies of fusion
inhibitors (36–38) but has not been explained.
The C-peptide Remains Accessible when Linked to Fusion
Partners—To ensure that linkage of C37-H6 to each of the
partner proteins did not affect the accessibility of C37 for
binding to a sterically open target, the fusion proteins and C37
were assayed for binding to IZN36, a soluble mimic of the
N-trimer (10), using SPR. Each fusion protein was flowed over
the control and IZN36 surfaces. C37 reversibly bound to IZN36
with a low nM KD (Fig. 3). The calculated KD for the fusion
proteins are clustered in a narrow range around the C37 value
(2-fold lower to 2-fold higher). The estimated kinetic parame-
ters are similarly clustered, ranging from 3.2-fold slower to
1.4-fold faster (association rate) and up to 3.2-fold slower (dis-
sociation rate). These rates are only approximate due to small
systematic deviations from the fitting model, but as expected
there is a slight trend toward slower association and dissocia-
tion rates with increasing molecular weight. These small dif-
ferences in binding kinetics are likely responsible for some of
the variation in potency observed here but rule out distinct
binding kinetics as the major contributor to the substantial
differences in potency among these inhibitors. These results
also show that the accessibility and affinity of C37 are not
significantly altered in the context of the fusion proteins. None
of the cargo proteins alone showed measurable association with
IZN36 at 100 nM (Fig. 3, inset).
Partial Restoration of Inhibitory Potency with Extended Gly/
Ser Linkers—To test whether a longer linker could overcome the
steric block and restore inhibitory potency of our weakest inhib-
itor, we extended the flexible linker in MBP-C37 from its original
length of 7 amino acids to 20 (MBP1-C37) or 33 (MBP2-C37)
using Gly/Ser residues (Table I). Both extended linker inhibitors
exhibit partial recovery of inhibitory potency. Compared with
MBP-C37, MBP1-C37 and MBP2-C37 are 2.3–2.9-fold and 2.6–
6.1-fold more potent, respectively (Table I). Compared withMBP-
C37, MBP1- and MBP2-C37 interact similarly with IZN36 as
measured by SPR (KD vary by 20%, ka and kd are 2-fold
higher). In contrast to the other cargo-C37 fusions, a significant
portion of the increased potency in MBP1- and MBP2-C37 may
be attributable to an increased association rate.
Stability of Fusion Proteins during Fusion Assays—Inhibi-
tors were analyzed for precipitation or extensive proteolysis to
demonstrate that these processes did not cause the observed
decrease in potency of the fusion proteins. C37 and the C37
FIG. 1.Model of HIV-1 membrane fusion pathway (adapted from Ref. 9). Formation of the trimer-of-hairpins drives the viral and cellular
membranes together, leading to fusion. The N-peptide region (gray), C-peptide region (blue), gp120 (green), gp41 (light blue), gp41 fusion peptide
(red), and transmembrane domain (purple) are shown. gp120 is removed from the prehairpin intermediate for clarity. Also shown are a series of
C37 fusion proteins of different sizes and an anti-N-trimer Ab attempting to access the N-trimer but potentially blocked by a steric restriction. Sizes
of the Ab and fusion proteins are only approximately to scale.
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fusions were incubated in tissue culture medium at 37 °C for
20 h to simulate the harshest conditions faced by the inhibitors
during the cell-cell fusion and viral infectivity assays. We ob-
served only trace (2%) degradation for all of the inhibitors
(data not shown), allowing us to conclude that proteolysis did
not cause a significant decrease in the potency of our inhibitors.
We cannot, however, rule out the contribution of minor proteo-
lytic breakdown products to increased inhibitory potency, par-
ticularly for the least potent inhibitors (1% contamination with
free C37 would result in an apparent cell-cell fusion IC50 value
of 100 nM for a completely inactive inhibitor). Therefore, the
described potencies of the inhibitors presented in this study
should be considered an upper limit. An anti-His tag Western
blot comparing samples before and after high speed centrifu-
gation revealed no precipitation (data not shown).
DISCUSSION
In principle, the gp41 N-trimer is an especially promising
inhibition target, but despite the generation of numerous Abs
with tight and specific binding against various mimics of the
N-trimer, none of these Abs displays broadly neutralizing ac-
tivity (reviewed in Ref. 17). Our results suggest that HIV may
have developed a strong steric defense against immune attack
for its critical N-trimer region. In this study we have shown
that the gp41 N-trimer region has poor accessibility to large
proteins. It is a logical extrapolation of the data presented here
that a protein as large as IgG (150 kDa), even though it forms
a somewhat elongated shape, will suffer a steric block at least
as severe as we observed with our largest protein, MBP (41
kDa), which is smaller than the individual (50 kDa) domains
of an IgG. This defense may be a major factor in frustrating
efforts to induce neutralizing Abs against the N-trimer region
and may also explain why such neutralizing Abs against the
N-trimer have not yet been observed in infected patients.
The steric restriction of the N-trimer stands in stark contrast
to apparent accessibility of the extreme C-terminal region of
the gp41 ectodomain (between the C-peptide region and the
transmembrane domain). The only known potent and broadly
neutralizing Abs against gp41 (2F5 and 4E10) target this re-
gion (22). Recent studies have suggested that this region may
adopt a helical or -strand conformation or cycle between the
two (33, 39). For the most thoroughly studied Ab against this
region, 2F5, a full-length IgG (150 kDa), is more potent than
the Fab (50 kDa) (33), suggesting a freely accessible site.
There is also evidence suggesting that the C-peptide region
may be more accessible than the N-trimer. The designed pro-
teins 5-helix (25 kDa) (9) and NCCG-gp41 (35 kDa) (40) target
the C-peptide region and are potent entry inhibitors. Recently,
a Pseudomonas endotoxin (PE) fusion with 5-helix (5-helix-PE,
TABLE I
IC50 (in nM) of fusion proteins in cell-cell fusion and viral infectivity assays
Protein Fusion partnermolecular mass
Cell-cell
fusion
IC50 ratio
(cell-cell fusion)
Viral infectivity
HXB2 IC50 ratio HXB2
Viral infectivity
JRFL
IC50 ratio
JRFL
kDa
C37 0 0.85 1.0 2.8 1.0 8.2 1.0
BPTI-C37 6.5 1.5 1.8 3.1 1.1 4.8 0.6
Ub-C37 8.6 4.7 5.5 6.8 2.5 37.7 4.6
Mb-C37 17 30.8 36.2 58.0 21.0 414 50.5
GFP-C37 27 28.9 34.0 118 42.8 533 65.0
MBP-C37 41 192 225 206 74.8 1874 228
MBP1-C37 41 75.1 88.4 88.9 32.2 640 78.0
MBP2-C37 41 31.2 36.7 79.2 28.7 516 62.9
IC50 S.E. is 25% for both assays. IC50 ratios are relative to C37.
FIG. 2. Inhibitory activity of C37 and C37 fusion proteins. Data points are averages of at least quadruplicate measurements. Data are
normalized to uninhibited fusion activity. a, cell-cell fusion assay (HXB2 Env). S.E. of each point is 0.05. b, viral infectivity assay (HXB2 Env).
S.E. of each point is 0.1. An overshoot is observed at low inhibitor concentrations (data above 1.0). Fitting the viral infectivity data to a simple
Langmuir equation with a fixed zero inhibitor point produces noticeable deviation from the data near the zero point because of this overshoot.
Fitting the data without fixing the zero inhibitor point (as done in this study) improves the quality of the fit but does not significantly affect the
relative IC50 values of the inhibitors.
FIG. 3. Binding of C37 and C37 fusion inhibitors to IZN36
measured by SPR. Responses for representative inhibitors were nor-
malized and overlaid to facilitate their comparison (thick traces). Fits to
the interaction model are included (thin traces). Inset, interaction of
control proteins (no C37) with IZN36 surface.
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65 kDa) was shown to inhibit viral entry with similar potency
as 5-helix (41), although a toxic effect from PE may mask a loss
of potency. Although the C-peptide region is likely accessible, it
is difficult to target for vaccine studies, as it is unclear what
organized structure (if any) this region adopts during viral
entry.
C37 inhibits viral fusion by binding along the full length of
the surface groove of the N-trimer, including the deep hydro-
phobic “pocket” region previously shown to be an essential
player in viral fusion. Inhibitors that specifically target this
pocket have been developed (10).2 In future studies, it will be
important to test such pocket-specific inhibitors to see whether
they can circumvent the steric block observed here. It will also
be important to check whether cargo fused to the C terminus of
C37 shows a similar pattern of steric blockage.
The steric block we observe in the gp41 N-trimer is reminis-
cent of steric restrictions observed in gp120. These restrictions
have been attributed to glycosylation (“glycan shield”) (42, 43)
and/or inaccessible antigens (38, 44, 45). Previous studies with
several broadly neutralizing gp120 Abs have shown that
smaller versions of these Abs (Fabs or scFvs) often have signif-
icantly improved potency despite a loss of avidity (38, 46). The
N-trimer steric block observed here may be more strict than
seen in gp120. Proteins the size of Fabs (50 kDa) and scFvs
(25 kDa) are already too large to fully access the gp41 N-
trimer. Interestingly, the N-trimer region does not contain any
glycosylation sites, probably because of its ultimate complete
burial in the six-helix bundle structure. The N-trimer, how-
ever, may be affected by nearby glycosylation sites in gp120 or
other regions of gp41 (the C-peptide region and N/C-peptide
connecting loop are extensively glycosylated). A glycosylation
site near the gp120 V3 loop has been shown to affect accessi-
bility of the 2F5 Ab to its gp41 epitope in resistant strains (43).
Implications for C-peptide Inhibitors—Our results suggest
that attempts to improve the longevity of C-peptide inhibitors
in the bloodstream may also be frustrated by steric issues. For
instance, T-20, a 36-residue peptide recently approved by the
FDA, is rapidly cleared from the bloodstream by kidney filtra-
tion, dramatically increasing dosing requirements. A reasona-
ble approach for prevention of this rapid clearance is to cross-
link C-peptide inhibitors to larger proteins (e.g. albumin) or
high molecular weight polyethylene glycol, which also can re-
duce peptide immunogenicity (47). Our results suggest that
these straightforward approaches will likely reduce the po-
tency of modified C-peptides, although use of smaller proteins
or low molecular weight polyethylene glycol may lessen this
effect. Our extended loop constructs suggest the possibility that
longer linkers between these bulking groups and the C-peptide
inhibitor could improve accessibility to the N-trimer. Stiffer
(e.g. helical) linkers may provide better separation from large
fusion partners and restore inhibitory potency better than the
flexible Gly/Ser linkers employed here.
An important caveat to applying our results to T-20 is that,
compared with C34, T-20 is derived from a gp41 sequence
shifted about 10 amino acids toward the C terminus and its
binding site extends beyond the N-trimer region. Although they
are thought to have a similar mechanism of action, T-20 and
C34 (and the similar T-1249) vary in their potencies against
different HIV-1 strains and their sensitivities to resistance
mutations (18, 48, 49).
Future Directions: Overcoming the Steric Block—We hope
that the observation of this steric block can be used to improve
the chances of discovering a broadly neutralizing Ab against
this valuable HIV target, rather than discouraging this effort.
Specifically, we suggest that a designed, sterically restricted
N-trimer antigen could be used to generate, boost, or screen for
potent neutralizing Abs able to overcome the steric block. Cur-
rently used mimics of the N-trimer region (e.g. 5-helix, IZN36,
NCCG-gp41) could be modified by attachment to bulky proteins
or large inert particles such that only Abs capable of penetrat-
ing a sterically recessed target would be selected.
Neutralizing Abs against sterically blocked gp120 targets
often utilize unusually long CDR H3 loops to access recessed
antigens (33, 46, 50). The insertion of longer linkers connecting
MBP to C37 results in partial recovery of inhibitory activity,
suggesting that extended CDR H3 loops may help penetrate
the steric block on the gp41 N-trimer. These Abs are difficult to
generate in small animals, as Abs in primates have longer CDR
H3 loops on average than rodents (51). Potent N-trimer Abs
may be more easily found using strategies that enrich for this
type of Ab (e.g. engineered Ab libraries, Ab phage display,
immunization of primates). Alternatively, very high affinity
(sub-nM) Abs against the N-trimer may still be sufficiently
neutralizing despite a substantial decrease in potency caused
by the steric block. Recently, Merck has reported preliminary
results on an antibody that binds to the N-trimer region and
possesses neutralizing activity against some HIV strains (52).
No detailed information on this Ab has yet been published, but
it will be interesting to see whether or how this Ab circumvents
the steric block we observe here (e.g. high affinity Ab that can
tolerate several hundred-fold loss in activity, extended variable
loops, specific targeting of a subsite in the N-trimer).
Finally, our results suggest that the traditional depiction
of the prehairpin intermediate as a symmetric structure (e.g.
Fig. 1) may be inaccurate. The steric block of the N-trimer
and apparent accessibility of the C-peptide region show that
they reside in very different environments. Possible sources
of this asymmetry include interactions with gp120, other
regions of gp41, or cell surface proteins as well as glycosyla-
tion and differences between the curvature of the viral and
cellular membranes.
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